Actinium Pharmaceuticals, Inc. experienced a significant increase in net loss for the first quarter of 2025, reaching $15.9 million compared to $8.7 million in the same period last year. This was primarily driven by higher research and development expenses and increased general and administrative costs, largely due to non-cash stock-based compensation.